Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 535

1.

Analysis of glutathione S-transferase and cytochrome P450 gene polymorphism in recipients of dose-adjusted busulfan-cyclophosphamide conditioning.

Terakura S, Onizuka M, Fukumoto M, Kuwatsuka Y, Kohno A, Ozawa Y, Miyamura K, Inagaki Y, Sawa M, Atsuta Y, Suzuki R, Naoe T, Morishita Y, Murata M; Nagoya Blood and Marrow Transplantation Group.

Int J Hematol. 2019 Sep 25. doi: 10.1007/s12185-019-02741-8. [Epub ahead of print]

PMID:
31555969
2.

ZNF384-fusion proteins have high affinity for the transcriptional coactivator EP300 and aberrant transcriptional activities.

Yamamoto H, Hayakawa F, Yasuda T, Odaira K, Minamikawa Y, Tange N, Hirano D, Kojima Y, Morishita T, Tsuzuki S, Naoe T, Kiyoi H.

FEBS Lett. 2019 Aug;593(16):2151-2161. doi: 10.1002/1873-3468.13506. Epub 2019 Jul 10.

PMID:
31234226
3.

Numerical Study on the Potential of Cavitation Damage in a Lead⁻Bismuth Eutectic Spallation Target.

Wan T, Naoe T, Kogawa H, Futakawa M, Obayashi H, Sasa T.

Materials (Basel). 2019 Feb 25;12(4). pii: E681. doi: 10.3390/ma12040681.

4.

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.

Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Döhner H, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Adès L, Avvisati G, Montesinos P, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F.

Blood. 2019 Apr 11;133(15):1630-1643. doi: 10.1182/blood-2019-01-894980. Epub 2019 Feb 25. Review.

5.

Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system.

Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T; New TARGET investigators.

Int J Hematol. 2019 Apr;109(4):426-439. doi: 10.1007/s12185-019-02613-1. Epub 2019 Feb 14.

PMID:
30762219
6.

Phase II study of FLAGM (fludarabine + high-dose cytarabine + granulocyte colony-stimulating factor + mitoxantrone) for relapsed or refractory acute myeloid leukemia.

Hatsumi N, Miyawaki S, Yamauchi T, Takeshita A, Komatsu N, Usui N, Arai Y, Ishida F, Morii T, Kano Y, Ogura M, Machida S, Nishii K, Honda S, Ohnishi K, Naoe T; Japan Adult Leukemia Study Group (JALSG).

Int J Hematol. 2019 Apr;109(4):418-425. doi: 10.1007/s12185-019-02606-0. Epub 2019 Feb 6.

PMID:
30725360
7.

Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation.

Miyamura K, Ohnishi K, Ohtake S, Usui N, Nakaseko C, Fujita H, Fujisawa S, Sakura T, Okumura H, Iriyama N, Emi N, Fujimaki K, Honda S, Miyazaki Y, Naoe T.

Blood Adv. 2019 Feb 12;3(3):312-319. doi: 10.1182/bloodadvances.2018025981.

8.

Potent antiproliferative effect of fatty-acid derivative AIC-47 on leukemic mice harboring BCR-ABL mutation.

Shinohara H, Sugito N, Kuranaga Y, Heishima K, Minami Y, Naoe T, Akao Y.

Cancer Sci. 2019 Feb;110(2):751-760. doi: 10.1111/cas.13913. Epub 2019 Jan 17.

9.

Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity.

Hirano D, Hayakawa F, Yasuda T, Tange N, Yamamoto H, Kojima Y, Morishita T, Imoto N, Tsuzuki S, Mano H, Naoe T, Kiyoi H.

Oncogene. 2019 Mar;38(13):2263-2274. doi: 10.1038/s41388-018-0573-9. Epub 2018 Nov 26.

PMID:
30478446
10.

Autophagic degradation determines the fate of T315I-mutated BCR-ABL protein.

Shinohara H, Minami Y, Naoe T, Akao Y.

Haematologica. 2019 May;104(5):e191-e194. doi: 10.3324/haematol.2018.194431. Epub 2018 Nov 22. No abstract available.

11.

Brief history of the Asiatic International Society of Hematology: our roots of international cooperation with Asian countries.

Saito H, Hotta T, Naoe T.

Int J Hematol. 2018 Dec;108(6):566-570. doi: 10.1007/s12185-018-2549-5. Epub 2018 Oct 12. Review.

PMID:
30315434
12.

Clinical significance of ASXL2 and ZBTB7A mutations and C-terminally truncated RUNX1-RUNX1T1 expression in AML patients with t(8;21) enrolled in the JALSG AML201 study.

Kawashima N, Akashi A, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kitamura K, Sakaida E, Takeshita A, Suzushima H, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group (JALSG).

Ann Hematol. 2019 Jan;98(1):83-91. doi: 10.1007/s00277-018-3492-5. Epub 2018 Sep 24.

PMID:
30251205
13.

Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study.

Takeshita A, Asou N, Atsuta Y, Sakura T, Ueda Y, Sawa M, Dobashi N, Taniguchi Y, Suzuki R, Nakagawa M, Tamaki S, Hagihara M, Fujimaki K, Furumaki H, Obata Y, Fujita H, Yanada M, Maeda Y, Usui N, Kobayashi Y, Kiyoi H, Ohtake S, Matsumura I, Naoe T, Miyazaki Y; and the Japanese Adult Leukemia Study Group.

Leukemia. 2019 Feb;33(2):358-370. doi: 10.1038/s41375-018-0233-7. Epub 2018 Aug 9.

PMID:
30093681
14.

Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open-label phase 1 study.

Usuki K, Sakura T, Kobayashi Y, Miyamoto T, Iida H, Morita S, Bahceci E, Kaneko M, Kusano M, Yamada S, Takeshita S, Miyawaki S, Naoe T.

Cancer Sci. 2018 Oct;109(10):3235-3244. doi: 10.1111/cas.13749.

15.

Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols.

Kato H, Fujita H, Akiyama N, Kimura SI, Hiramoto N, Hosono N, Takahashi T, Shigeno K, Minamiguchi H, Miyatake J, Handa H, Kanda Y, Yoshida M, Miyawaki S, Ohtake S, Naoe T, Kiyoi H, Matsumura I, Miyazaki Y; Japan Adult Leukemia Study Group.

Support Care Cancer. 2018 Dec;26(12):4187-4198. doi: 10.1007/s00520-018-4292-0. Epub 2018 Jun 2.

PMID:
29860713
16.

Generation of TCR-Expressing Innate Lymphoid-like Helper Cells that Induce Cytotoxic T Cell-Mediated Anti-leukemic Cell Response.

Ueda N, Uemura Y, Zhang R, Kitayama S, Iriguchi S, Kawai Y, Yasui Y, Tatsumi M, Ueda T, Liu TY, Mizoro Y, Okada C, Watanabe A, Nakanishi M, Senju S, Nishimura Y, Kuzushima K, Kiyoi H, Naoe T, Kaneko S.

Stem Cell Reports. 2018 Jun 5;10(6):1935-1946. doi: 10.1016/j.stemcr.2018.04.025. Epub 2018 May 24.

17.

Transcriptional activities of DUX4 fusions in B-cell acute lymphoblastic leukemia.

Tanaka Y, Kawazu M, Yasuda T, Tamura M, Hayakawa F, Kojima S, Ueno T, Kiyoi H, Naoe T, Mano H.

Haematologica. 2018 Nov;103(11):e522-e526. doi: 10.3324/haematol.2017.183152. Epub 2018 May 17. No abstract available.

18.

Final analysis of the JALSG Ph+ALL202 study: tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL.

Hatta Y, Mizuta S, Matsuo K, Ohtake S, Iwanaga M, Sugiura I, Doki N, Kanamori H, Ueda Y, Yoshida C, Dobashi N, Maeda T, Yujiri T, Monma F, Ito Y, Hayakawa F, Takeuchi J, Kiyoi H, Miyazaki Y, Naoe T.

Ann Hematol. 2018 Sep;97(9):1535-1545. doi: 10.1007/s00277-018-3323-8. Epub 2018 Apr 24.

19.

Analysis of the oligomeric states of nucleophosmin using size exclusion chromatography.

Sakashita G, Kiyoi H, Naoe T, Urano T.

Sci Rep. 2018 Mar 5;8(1):4008. doi: 10.1038/s41598-018-22359-w.

20.

Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200.

Harada K, Doki N, Miyazaki Y, Wakita A, Ohtake S, Takada S, Komatsu H, Kubo K, Takeshita A, Adachi Y, Kiyoi H, Yamaguchi T, Yoshida M, Naoe T, Ohashi K.

Ann Hematol. 2018 Aug;97(8):1481-1483. doi: 10.1007/s00277-018-3281-1. Epub 2018 Mar 1. No abstract available.

PMID:
29497807
21.

Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study.

Harada Y, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, Miyawaki S, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Onizuka M, Takeshita A, Ishida F, Suzushima H, Ishizawa K, Naoe T, Matsumura I, Miyazaki Y, Ogawa S, Kiyoi H; Japan Adult Leukemia Study Group JALSG.

Leuk Res. 2018 Mar;66:20-27. doi: 10.1016/j.leukres.2018.01.008. Epub 2018 Jan 17.

PMID:
29360622
22.

Distinct gene alterations with a high percentage of myeloperoxidase-positive leukemic blasts in de novo acute myeloid leukemia.

Kamijo R, Itonaga H, Kihara R, Nagata Y, Hata T, Asou N, Ohtake S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Ogawa S, Naoe T, Kiyoi H, Miyazaki Y.

Leuk Res. 2018 Feb;65:34-41. doi: 10.1016/j.leukres.2017.12.006. Epub 2018 Jan 2.

PMID:
29306105
23.

Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201.

Harada K, Doki N, Hagino T, Miyawaki S, Ohtake S, Kiyoi H, Miyazaki Y, Fujita H, Usui N, Okumura H, Miyamura K, Nakaseko C, Fujieda A, Nagai T, Yamane T, Sakamaki H, Ohnishi K, Naoe T, Ohno R, Ohashi K.

Ann Hematol. 2018 Jan;97(1):73-81. doi: 10.1007/s00277-017-3156-x. Epub 2017 Dec 2.

PMID:
29196987
24.

A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.

Yamaura T, Nakatani T, Uda K, Ogura H, Shin W, Kurokawa N, Saito K, Fujikawa N, Date T, Takasaki M, Terada D, Hirai A, Akashi A, Chen F, Adachi Y, Ishikawa Y, Hayakawa F, Hagiwara S, Naoe T, Kiyoi H.

Blood. 2018 Jan 25;131(4):426-438. doi: 10.1182/blood-2017-05-786657. Epub 2017 Nov 29.

PMID:
29187377
25.

Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.

Kuwatsuka Y, Tomizawa D, Kihara R, Nagata Y, Shiba N, Iijima-Yamashita Y, Shimada A, Deguchi T, Miyachi H, Tawa A, Taga T, Kinoshita A, Nakayama H, Kiyokawa N, Saito AM, Koh K, Goto H, Kosaka Y, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Ogawa S, Naoe T, Hayashi Y, Horibe K, Manabe A, Mizutani S, Adachi S, Kiyoi H.

Int J Hematol. 2018 Feb;107(2):201-210. doi: 10.1007/s12185-017-2340-z. Epub 2017 Oct 12.

PMID:
29027108
26.

Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.

Takahashi N, Tauchi T, Kitamura K, Miyamura K, Saburi Y, Hatta Y, Miyata Y, Kobayashi S, Usuki K, Matsumura I, Minami Y, Usui N, Fukuda T, Takada S, Ishikawa M, Fujimaki K, Gomyo H, Sasaki O, Ohishi K, Miyake T, Imai K, Suzushima H, Mitsui H, Togitani K, Kiguchi T, Atsuta Y, Ohtake S, Ohnishi K, Kobayashi Y, Kiyoi H, Miyazaki Y, Naoe T; Japan Adult Leukemia Study Group.

Int J Hematol. 2018 Feb;107(2):185-193. doi: 10.1007/s12185-017-2334-x. Epub 2017 Sep 19.

PMID:
28929332
27.

High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG.

Sakura T, Hayakawa F, Sugiura I, Murayama T, Imai K, Usui N, Fujisawa S, Yamauchi T, Yujiri T, Kakihana K, Ito Y, Kanamori H, Ueda Y, Miyata Y, Kurokawa M, Asou N, Ohnishi K, Ohtake S, Kobayashi Y, Matsuo K, Kiyoi H, Miyazaki Y, Naoe T.

Leukemia. 2018 Mar;32(3):626-632. doi: 10.1038/leu.2017.283. Epub 2017 Sep 15.

PMID:
28914260
28.

Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS.

Tawara I, Kageyama S, Miyahara Y, Fujiwara H, Nishida T, Akatsuka Y, Ikeda H, Tanimoto K, Terakura S, Murata M, Inaguma Y, Masuya M, Inoue N, Kidokoro T, Okamoto S, Tomura D, Chono H, Nukaya I, Mineno J, Naoe T, Emi N, Yasukawa M, Katayama N, Shiku H.

Blood. 2017 Nov 2;130(18):1985-1994. doi: 10.1182/blood-2017-06-791202. Epub 2017 Aug 31.

PMID:
28860210
29.

Effects of Grain Size on Ultrasonic Attenuation in Type 316L Stainless Steel.

Wan T, Naoe T, Wakui T, Futakawa M, Obayashi H, Sasa T.

Materials (Basel). 2017 Jul 5;10(7). pii: E753. doi: 10.3390/ma10070753.

30.

Management of infection during chemotherapy for acute leukemia in Japan: a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group.

Kimura SI, Fujita H, Kato H, Hiramoto N, Hosono N, Takahashi T, Shigeno K, Hatsumi N, Minamiguchi H, Miyatake J, Handa H, Akiyama N, Kanda Y, Yoshida M, Kiyoi H, Miyazaki Y, Naoe T; Japan Adult Leukemia Study Group (JALSG).

Support Care Cancer. 2017 Nov;25(11):3515-3521. doi: 10.1007/s00520-017-3775-8. Epub 2017 Jun 6.

PMID:
28584934
31.

Phase II study of intrabone single unit cord blood transplantation for hematological malignancies.

Murata M, Maeda Y, Masuko M, Onishi Y, Endo T, Terakura S, Ishikawa Y, Iriyama C, Ushijima Y, Goto T, Fujii N, Tanimoto M, Kobayashi H, Shibasaki Y, Fukuhara N, Inamoto Y, Suzuki R, Kodera Y, Matsushita T, Kiyoi H, Naoe T, Nishida T.

Cancer Sci. 2017 Aug;108(8):1634-1639. doi: 10.1111/cas.13291. Epub 2017 Jun 29.

32.

Phase I study of glasdegib (PF-04449913), an oral smoothened inhibitor, in Japanese patients with select hematologic malignancies.

Minami Y, Minami H, Miyamoto T, Yoshimoto G, Kobayashi Y, Munakata W, Onishi Y, Kobayashi M, Ikuta M, Chan G, Woolfson A, Ono C, Shaik MN, Fujii Y, Zheng X, Naoe T.

Cancer Sci. 2017 Aug;108(8):1628-1633. doi: 10.1111/cas.13285. Epub 2017 Jun 19.

33.

Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia.

Togasaki E, Takeda J, Yoshida K, Shiozawa Y, Takeuchi M, Oshima M, Saraya A, Iwama A, Yokote K, Sakaida E, Hirase C, Takeshita A, Imai K, Okumura H, Morishita Y, Usui N, Takahashi N, Fujisawa S, Shiraishi Y, Chiba K, Tanaka H, Kiyoi H, Ohnishi K, Ohtake S, Asou N, Kobayashi Y, Miyazaki Y, Miyano S, Ogawa S, Matsumura I, Nakaseko C, Naoe T.

Blood Cancer J. 2017 Apr 28;7(4):e559. doi: 10.1038/bcj.2017.36.

34.

Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study.

Tojo A, Kyo T, Yamamoto K, Nakamae H, Takahashi N, Kobayashi Y, Tauchi T, Okamoto S, Miyamura K, Hatake K, Iwasaki H, Matsumura I, Usui N, Naoe T, Tugnait M, Narasimhan NI, Lustgarten S, Farin H, Haluska F, Ohyashiki K.

Int J Hematol. 2017 Sep;106(3):385-397. doi: 10.1007/s12185-017-2238-9. Epub 2017 Apr 25.

PMID:
28444644
35.

Phase II study of imatinib-based chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia.

Fujisawa S, Mizuta S, Akiyama H, Ueda Y, Aoyama Y, Hatta Y, Kakihana K, Dobashi N, Sugiura I, Onishi Y, Maeda T, Imai K, Ohtake S, Miyazaki Y, Ohnishi K, Matsuo K, Naoe T.

Am J Hematol. 2017 Apr;92(4):367-374. doi: 10.1002/ajh.24653. Epub 2017 Feb 21.

36.

Biosynthesis of the Carbonylmethylene Structure Found in the Ketomemicin Class of Pseudotripeptides.

Kawata J, Naoe T, Ogasawara Y, Dairi T.

Angew Chem Int Ed Engl. 2017 Feb 13;56(8):2026-2029. doi: 10.1002/anie.201611005. Epub 2017 Jan 18.

37.

Impact of T-cell chimerism on relapse after cord blood transplantation for hematological malignancies: Nagoya Blood and Marrow Transplantation Group study.

Yokohata E, Kuwatsuka Y, Ohashi H, Terakura S, Kawashima N, Seto A, Kurahashi S, Ozawa Y, Goto T, Imahashi N, Nishida T, Miyao K, Sakemura R, Kato T, Sawa M, Kohno A, Sao H, Iida H, Kiyoi H, Naoe T, Miyamura K, Murata M.

Bone Marrow Transplant. 2017 Apr;52(4):612-614. doi: 10.1038/bmt.2016.323. Epub 2017 Jan 9. No abstract available.

PMID:
28067879
38.

Corrigendum: Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults.

Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H.

Nat Genet. 2016 Nov 29;48(12):1591. doi: 10.1038/ng1216-1587a. No abstract available.

PMID:
27898077
39.

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD.

Blood. 2017 Jan 26;129(4):424-447. doi: 10.1182/blood-2016-08-733196. Epub 2016 Nov 28. Review.

40.

Somatic PHF6 mutations in 1760 cases with various myeloid neoplasms.

Mori T, Nagata Y, Makishima H, Sanada M, Shiozawa Y, Kon A, Yoshizato T, Sato-Otsubo A, Kataoka K, Shiraishi Y, Chiba K, Tanaka H, Ishiyama K, Miyawaki S, Mori H, Nakamaki T, Kihara R, Kiyoi H, Koeffler HP, Shih LY, Miyano S, Naoe T, Haferlach C, Kern W, Haferlach T, Ogawa S, Yoshida K.

Leukemia. 2016 Nov;30(11):2270-2273. doi: 10.1038/leu.2016.212. Epub 2016 Aug 1. No abstract available.

PMID:
27479181
41.

Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells.

Fukushima N, Minami Y, Kakiuchi S, Kuwatsuka Y, Hayakawa F, Jamieson C, Kiyoi H, Naoe T.

Cancer Sci. 2016 Oct;107(10):1422-1429. doi: 10.1111/cas.13019. Epub 2016 Sep 2.

42.

The photosensitizer verteporfin has light-independent anti-leukemic activity for Ph-positive acute lymphoblastic leukemia and synergistically works with dasatinib.

Morishita T, Hayakawa F, Sugimoto K, Iwase M, Yamamoto H, Hirano D, Kojima Y, Imoto N, Naoe T, Kiyoi H.

Oncotarget. 2016 Aug 30;7(35):56241-56252. doi: 10.18632/oncotarget.11025.

43.

Fibroblast Growth Factor-2 facilitates the growth and chemo-resistance of leukemia cells in the bone marrow by modulating osteoblast functions.

Sugimoto K, Miyata Y, Nakayama T, Saito S, Suzuki R, Hayakawa F, Nishiwaki S, Mizuno H, Takeshita K, Kato H, Ueda R, Takami A, Naoe T.

Sci Rep. 2016 Aug 2;6:30779. doi: 10.1038/srep30779.

44.

SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway.

Takagi Y, Shimada K, Shimada S, Sakamoto A, Naoe T, Nakamura S, Hayakawa F, Tomita A, Kiyoi H.

Cancer Sci. 2016 Sep;107(9):1270-80. doi: 10.1111/cas.13001. Epub 2016 Sep 6.

45.

Co-expression of wild-type FLT3 attenuates the inhibitory effect of FLT3 inhibitor on FLT3 mutated leukemia cells.

Chen F, Ishikawa Y, Akashi A, Naoe T, Kiyoi H.

Oncotarget. 2016 Jul 26;7(30):47018-47032. doi: 10.18632/oncotarget.10147.

46.

Validation of a rapid one-step high sensitivity real-time quantitative PCR system for detecting major BCR-ABL1 mRNA on an International Scale.

Yoshida C, Nakamae H, Fletcher L, Koga D, Sogabe T, Matsumura I, Kanakura Y, Branford S, Naoe T.

Springerplus. 2016 May 10;5:569. doi: 10.1186/s40064-016-2258-6. eCollection 2016.

47.

PAX5 tyrosine phosphorylation by SYK co-operatively functions with its serine phosphorylation to cancel the PAX5-dependent repression of BLIMP1: A mechanism for antigen-triggered plasma cell differentiation.

Inagaki Y, Hayakawa F, Hirano D, Kojima Y, Morishita T, Yasuda T, Naoe T, Kiyoi H.

Biochem Biophys Res Commun. 2016 Jun 24;475(2):176-81. doi: 10.1016/j.bbrc.2016.05.067. Epub 2016 May 13.

PMID:
27181361
48.

BCR-ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells.

Ueda N, Zhang R, Tatsumi M, Liu TY, Kitayama S, Yasui Y, Sugai S, Iwama T, Senju S, Okada S, Nakatsura T, Kuzushima K, Kiyoi H, Naoe T, Kaneko S, Uemura Y.

Cell Mol Immunol. 2018 Jan;15(1):15-26. doi: 10.1038/cmi.2016.7. Epub 2016 May 15.

49.

Prognostic significance of Wilms tumor 1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes.

Kobayashi S, Ueda Y, Nannya Y, Shibayama H, Tamura H, Ogata K, Akatsuka Y, Usuki K, Ito Y, Okada M, Suzuki T, Hata T, Matsuda A, Tohyama K, Kakumoto K, Koga D, Mitani K, Naoe T, Sugiyama H, Takaku F.

Cancer Biomark. 2016 Mar 31;17(1):21-32. doi: 10.3233/CBM-160612.

PMID:
27062571
50.

Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults.

Yasuda T, Tsuzuki S, Kawazu M, Hayakawa F, Kojima S, Ueno T, Imoto N, Kohsaka S, Kunita A, Doi K, Sakura T, Yujiri T, Kondo E, Fujimaki K, Ueda Y, Aoyama Y, Ohtake S, Takita J, Sai E, Taniwaki M, Kurokawa M, Morishita S, Fukayama M, Kiyoi H, Miyazaki Y, Naoe T, Mano H.

Nat Genet. 2016 May;48(5):569-74. doi: 10.1038/ng.3535. Epub 2016 Mar 28. Erratum in: Nat Genet. 2016 Nov 29;48(12 ):1591.

PMID:
27019113

Supplemental Content

Support Center